An act to add and repeal Section 1348.97 of the Health and Safety Code, to add and repeal Section 10127.25 of the Insurance Code, and to add and repeal Section 14124.17 of the Welfare and Institutions Code, relating to health care coverage.
AB 877 would require the Department of Managed Health Care, the Department of Insurance, and the State Department of Health Care Services to each send a one-time letter to the chief financial officer of every California health care service plan, health insurer, and Medi-Cal managed care plan that covers substance use disorder treatment in residential facilities. The letters would state that treatment in licensed, certified, or unlicensed residential facilities is almost exclusively nonmedical, with rare exceptions, and would explain when medical treatment is allowed and how nonmedical treatment should be billed. The bill defines “residential facility” broadly to include family homes, group care facilities, certified alcohol and drug programs, licensed recovery/treatment facilities, and recovery residences.
The measure is structured as a temporary, informational directive rather than a permanent regulatory overhaul. It would require the letters to be sent by October 1, 2026, and would repeal the new provisions on January 1, 2027. The bill applies across three coverage systems: commercial health plans regulated by DMHC, health insurers regulated by the Department of Insurance, and Medi-Cal managed care plans administered through DHCS.
In practical terms, AB 877 is intended to influence how plans classify and pay for substance use disorder services delivered in residential settings, especially by reinforcing that most such services are nonmedical and should be billed accordingly. It would not directly change benefit mandates or create a new coverage category, but it would add a statutory communication requirement that could affect claims handling, utilization review, and reimbursement practices for residential SUD treatment providers and the plans that pay them.
The available legislative record shows little public controversy in the materials provided. The bill had a majority key vote designation and no recorded committee transcript or vote breakdown in the context supplied, suggesting limited documented debate at this stage. The overall tone appears administrative and corrective, aimed at clarifying billing expectations for insurers and plans rather than expanding or restricting coverage in a more sweeping way.
The main point of potential contention is the bill’s premise that substance use disorder treatment in residential facilities is “almost exclusively nonmedical,” which may be viewed by providers or advocates as an oversimplification of clinically intensive residential care. Plans and regulators may support the clarification because it could reduce billing disputes, while some treatment providers may be concerned that the directive could be used to deny or downcode services that they believe require medical billing in certain cases.
AB 877 would add temporary sections to the Health and Safety Code, Insurance Code, and Welfare and Institutions Code requiring state regulators to notify plans and insurers about billing rules for substance use disorder treatment in residential facilities. It would affect DMHC-regulated health care service plans, DOI-regulated health insurers, and Medi-Cal managed care plans, as well as residential SUD providers whose claims are billed to those entities. The bill does not create a new benefit mandate, but it could influence interpretation and enforcement of existing coverage and billing requirements for residential substance use disorder services.
Based on the bill text and the limited legislative history provided, the sentiment appears generally supportive or at least noncontroversial in committee. The measure is framed as a clarification effort for regulators and payers, and the absence of recorded opposition, amendments in the provided context, or committee testimony suggests there was not a visible public dispute in the materials available. The bill’s majority key vote designation also points to a favorable posture among those who advanced it.
The most notable area of contention is the bill’s assertion that substance use disorder treatment in licensed, certified, or unlicensed residential facilities is almost always nonmedical. Supporters likely view that statement as a needed clarification to prevent improper billing, while critics could argue that residential treatment often includes clinically significant services and that a blanket characterization may not fit all settings or episodes of care. Another possible point of concern is that the bill relies on a one-time letter rather than a more direct statutory or regulatory fix, which may be seen as too limited by those seeking stronger enforcement or too prescriptive by those worried about administrative overreach.